Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience-Reference-Cited by-同舟云学术

Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience

Published:2021-09 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Moretti Marina^ORCID,Liberati Anna Marina,Rigacci Luigi^ORCID,Puccini Benedetta,Pulsoni Alessandro^ORCID,Gini Guido,Galieni Piero,Fabbri Alberto^ORCID,Cantonetti Maria,Pavone Vincenzo,Bolis Silvia,Botto Barbara,Renzi Daniela,Falchi Lorenzo^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496);Gordon;J Clin Oncol,2013

2. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

3. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial;Schmitz;Lancet,2002

4. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma;Moskowitz;Blood,2010

5. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma;Moskowitz;Blood,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Very late relapse in Hodgkin lymphoma: Characterizing an understudied population;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. Bendamustine/brentuximab vedotin;Reactions Weekly;2022-12-10

3. Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review;Frontiers in Oncology;2022-07-14